BioCryst Pharmaceuticals (NASDAQ:BCRX) is one of today's worst performing low-priced stocks, down 10.1% to $1.24 on 1.0x average daily volume. BioCryst Pharmaceuticals has traded 516,000 shares thus far today, vs. average volume of 507,000 shares per day. The stock has underperformed the Dow (-10.1% to the Dow's -0.5%) and underperformed the S&P 500 (-10.1% to the S&P's -0.8%) during today's trading.

Potential upside of 121.6% exists for BioCryst Pharmaceuticals, based on a current level of $1.24 and analysts' average consensus price target of $2.75. The stock should find initial resistance at its 50-day moving average (MA) of $1.56 and further resistance at its 200-day MA of $3.08.

BioCryst Pharmaceuticals, Inc., a biopharmaceutical company, discovers and designs novel small-molecule pharmaceuticals using structure-based drug design. The Company's products are used for the treatment of immunological, viral, and cardiovascular diseases and disorders. BioCryst's lead immunological drug program targets T-cell proliferative disorders.

In the past 52 weeks, BioCryst Pharmaceuticals share prices have been bracketed by a low of $1.08 and a high of $5.95 and are now at $1.24, 15% above that low price. The 200-day and 50-day moving averages have moved 0.7% lower and 0.08% lower over the past week, respectively.

SmarTrend is tracking the current trend status for BioCryst Pharmaceuticals and will alert subscribers who have BCRX in their portfolio or watchlist when shares have changed trend direction.